During the last session, Palisade Bio Inc (NASDAQ:PALI)’s traded shares were 68.0 million, with the beta value of the company hitting 1.39. At the end of the trading day, the stock’s price was $2.36, reflecting an intraday gain of 68.57% or $0.96. The 52-week high for the PALI share is $22.35, that puts it down -847.03 from that peak though still a striking 41.53% gain since the share price plummeted to a 52-week low of $1.38. The company’s market capitalization is $3.37M, and the average intraday trading volume over the past 10 days was 0.18 million shares, and the average trade volume was 109.30K shares over the past three months.
Palisade Bio Inc (PALI) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.00. PALI has a Sell rating from 0 analyst(s) out of 1 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 1 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -2.58.
Palisade Bio Inc (NASDAQ:PALI) trade information
Palisade Bio Inc (PALI) registered a 68.57% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 68.57% in intraday trading to $2.36, hitting a weekly high. The stock’s 5-day price performance is 34.86%, and it has moved by -0.84% in 30 days. Based on these gigs, the overall price performance for the year is -72.69%. The short interest in Palisade Bio Inc (NASDAQ:PALI) is 43112.0 shares and it means that shorts have 0.29 day(s) to cover.
The consensus price target of analysts on Wall Street is $1.5, which implies a decrease of -57.33% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $1.5 and $1.5 respectively. As a result, PALI is trading at a premium of 36.44% off the target high and 36.44% off the low.
Palisade Bio Inc (PALI) estimates and forecasts
Statistics show that Palisade Bio Inc has outperformed its competitors in share price, compared to the industry in which it operates. Palisade Bio Inc (PALI) shares have gone down -48.02% during the last six months, with a year-to-date growth rate more than the industry average at 53.95% against 17.10. In the rating firms’ projections, revenue will decrease -100.00% compared to the previous financial year.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 75.28%. While earnings are projected to return 54.26% in 2024.
PALI Dividends
Palisade Bio Inc is due to release its next quarterly earnings in January. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
Palisade Bio Inc (NASDAQ:PALI)’s Major holders
Palisade Bio Inc insiders own 1.88% of total outstanding shares while institutional holders control 3.58%, with the float percentage being 3.65%.